Amphastar Pharmaceuticals, Inc. 10-K

Item 2. Properties. Our manufacturing facilities are located in Rancho Cucamonga and South El Monte, California; Canton, Massachusetts; Éragny-sur-Epte, France; and Nanjing, China. As of December 31, 2025, we own or lease a total of 69 buildings at six locations in the U.S., France and China, that comprise 2.5 million square feet of manufacturing, research and development, distribution, packaging, laboratory, office and warehouse space. Our facilities are regularly inspected by the FDA in connection with our product approvals, and we believe that all of our facilities are being operated in material compliance with the FDA’s cGMP regulations. The following table provides a summary of our owned properties: ​ ​ ​ ​ ​ ​ ​ ​ ​ Aggregate ​ ​ ​ ​ ​ ​ Facility Size ​ ​ Location ​ (in square feet) ​ Primary Use Rancho Cucamonga, CA 267,674 Headquarters, research and development, laboratories, manufacturing, packaging, warehousing and administrative offices Éragny-sur-Epte, France 251,983 Manufacturing, laboratories, warehousing and administrative offices Canton, MA 216,590 Manufacturing, packaging, warehousing, distribution and administrative offices Nanjing, China 1,103,737 Manufacturing, procurement, research and development, warehousing, and administrative offices Chino, CA 57,968 Research and development, and laboratories South El Monte, CA 21,200 Manufacturing ​ The properties leased by us have expiration dates ranging from 2026 to 2035 (including certain renewal options). The following table provides a summary of our leased properties: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Aggregate ​ ​ ​ ​ ​ ​ Facility Size ​ ​ Location ​ (in square feet) ​ Primary Use Rancho Cucamonga, CA 191,180 Warehousing, distribution and administrative offices South El Monte, CA 343,413 Manufacturing, packaging, warehousing, distribution and administrative offices ​ We believe that our current manufacturing capacity is adequate for the near term. However, we are planning to increase capacity at our plant in Rancho Cucamonga, CA which should allow us to eventually quadruple the number of units produced at this facility. We are also increasing the capacity of our inhalation facility in Canton, MA and our insulin API production facility at ANP. We have in the past approached capacity at one of our facilities largely as a result of the FDA’s request that we reintroduce certain previously discontinued products to help cope with a nationwide shortage of these products. We believe that these capacity issues have been ameliorated as a result of certain other manufacturers re-entering the market and increasing the production of the products that were subject to the shortage. ​